CliffBio
biologic

Hemgenix

etranacogene dezaparvovec-drlb

Loss of exclusivityNovember 2034FDA regulatory exclusivity expiry
CompanyCSL Behring →View the full company profile on CliffBio

Drug detail

Brand nameHemgenix
Active ingredientetranacogene dezaparvovec-drlb
Strength1X10E13GENOME COPIES/ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2022
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Hemgenix patent cliff — loss of exclusivity November 2034 | CliffBio